Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast

• Event to take place on May 4, 2020 at 10:00 am (ET) / 4:00 pm (CET)
  
  

Daix (France), April 21, 2020 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, today announced that it will host a webcast presentation with two Key Opinion Leaders on May 4, 2020 to provide an update on its Phase IIb NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial evaluating lanifibranor for the treatment of NASH ahead of the release of headline results, which is expected in June 2020.

With the participation of Prof. Sven Francque, M.D., Antwerp University Hospital, co-principal investigator of the NATIVE clinical trial, and Prof. Pierre Bedossa, M.D., Paris-Diderot University, the central pathologist in charge of the biopsy analyses of the NATIVE clinical trial, the Company will discuss the trial design and present the characteristics of the patient population. At this stage, the trial remains blinded, in line with the protocol.

During this event, which had initially been scheduled to take place during the International Liver Congress 2020 (European Association for the Study of the Liver), Inventiva will explain the methodology used for the analysis of patient biopsies in the NATIVE clinical trial, and compare the different screening approaches currently used in NASH clinical trials, in particular the Steatosis, Activity, Fibrosis (“SAF") and NAFLD Activity Score (“NAS") scoring systems.

Pierre Broqua, CSO and cofounder of Inventiva, said: "After the analysis of all biopsies in the NATIVE clinical trial announced in mid-March, this webcast represents the last event before the expected publication of the trial’s headline results in June 2020. Prior to the clinical data release, we would like to review the different aspects of the trial in detail and we are delighted to benefit, on this occasion, from the participation of Prof. Sven Francque and Prof. Pierre Bedossa, two highly recognized experts in the NASH field. In particular, we will focus on how the trial design and our innovative screening strategy based on the SAF score enabled us to meet our patient recruitment objectives, including a high percentage of patients with severe steatohepatitis associated with advanced fibrosis.”